Quarterly report pursuant to Section 13 or 15(d)

STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY

v3.20.2
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Common stock
Additional Paid in Capital
Accumulated Deficit
Total
Beginning Balance at Dec. 31, 2018 $ 16 $ 62,593 $ (23,720) $ 38,889
Beginning Balance (in shares) at Dec. 31, 2018 15,663,221      
Stock-based compensation   682   682
Exercise of stock options   1   1
Exercise of stock options (in shares) 2,581      
Net loss     (7,204) (7,204)
Ending Balance at Mar. 31, 2019 $ 16 63,276 (30,924) 32,368
Ending Balance (in shares) at Mar. 31, 2019 15,665,802      
Beginning Balance at Dec. 31, 2018 $ 16 62,593 (23,720) 38,889
Beginning Balance (in shares) at Dec. 31, 2018 15,663,221      
Net loss       (15,675)
Ending Balance at Jun. 30, 2019 $ 16 64,536 (39,395) 25,157
Ending Balance (in shares) at Jun. 30, 2019 15,687,546      
Beginning Balance at Mar. 31, 2019 $ 16 63,276 (30,924) 32,368
Beginning Balance (in shares) at Mar. 31, 2019 15,665,802      
Issuance of common stock, net of issuance costs   230   230
Issuance of common stock, net of issuance costs (in shares) 21,744      
Stock-based compensation   1,030   1,030
Net loss     (8,471) (8,471)
Ending Balance at Jun. 30, 2019 $ 16 64,536 (39,395) 25,157
Ending Balance (in shares) at Jun. 30, 2019 15,687,546      
Beginning Balance at Dec. 31, 2019 $ 18 83,565 (56,688) $ 26,895
Beginning Balance (in shares) at Dec. 31, 2019 18,087,382     18,087,382
Issuance of common stock, net of issuance costs $ 2 68,809   $ 68,811
Issuance of common stock, net of issuance costs (in shares) 2,300,000      
Purchase and cancellation of shares from BioXcel Corporation   (9,024)   (9,024)
Purchase and cancellation of shares from BioXcel Corporation (in shares) (300,000)      
Stock-based compensation   776   776
Exercise of stock options   39   39
Exercise of stock options (in shares) 95,000      
Net loss     (14,911) (14,911)
Ending Balance at Mar. 31, 2020 $ 20 144,165 (71,599) 72,586
Ending Balance (in shares) at Mar. 31, 2020 20,182,382      
Beginning Balance at Dec. 31, 2019 $ 18 83,565 (56,688) $ 26,895
Beginning Balance (in shares) at Dec. 31, 2019 18,087,382     18,087,382
Purchase and cancellation of shares from BioXcel Corporation (in shares)       (300,000)
Net loss       $ (36,330)
Ending Balance at Jun. 30, 2020 $ 20 146,392 (93,018) $ 53,394
Ending Balance (in shares) at Jun. 30, 2020 20,352,913     20,352,913
Beginning Balance at Mar. 31, 2020 $ 20 144,165 (71,599) $ 72,586
Beginning Balance (in shares) at Mar. 31, 2020 20,182,382      
Stock-based compensation   1,956   1,956
Exercise of stock options   271   271
Exercise of stock options (in shares) 170,531      
Net loss     (21,419) (21,419)
Ending Balance at Jun. 30, 2020 $ 20 $ 146,392 $ (93,018) $ 53,394
Ending Balance (in shares) at Jun. 30, 2020 20,352,913     20,352,913